MBRX News and Press, Moleculin Biotech Inc. From 03/30/21

Moleculin Receives FDA Approval of Fast Track Designation for Annamycin in the Treatment of Sarcoma Lung Metastases PR Newswire HOUSTON , March 30, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage phar...

Moleculin Biotech (MBRX): FY GAAP EPS of -$1.76 beats by $0.37.Cash and cash equivalents of $15.17MPress Release For further details see: Moleculin Biotech EPS beats by $0.37

Moleculin Biotech, Inc. Reports Financial Results for the Year Ended December 31, 2020 PR Newswire HOUSTON , March 24, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a br...

Moleculin to Participate in Four Upcoming Healthcare Conferences PR Newswire HOUSTON , March 9, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candida...

Moleculin Biotech (MBRX) announces that the underwriters of its recent public offering have exercised their option to purchase an additional 2.14M shares at the public offering price of $4.75 per share.Moleculin has now sold a total of 16.4M shares in the offering for gross proceeds of about ...

Moleculin Announces Full Exercise of Over-Allotment Option Increases Gross Proceeds to Approximately $78 Million PR Newswire HOUSTON , Feb. 10, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharm...

Today, we take our first in-depth look at a small-cap oncology name that's deep in Busted IPO territory called Moleculin Biotech. The company recently posted some encouraging trial results and did a capital raise to address its short-term funding needs. A full investment analysis ...

Moleculin Announces Grant Awarded to Polish Research Institute for Independent Clinical Trial of Annamycin in Sarcoma Lung Metastases PR Newswire HOUSTON , Feb. 8, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a cli...

Moleculin Biotech (MBRX) announces that a preclinical study in animals demonstrated a potentially significant therapeutic benefit of Annamycin against metastatic osteosarcoma.In addition to the preclinical study results announced on February 2, the survival rate for Annamycin-treated animals ...

VANCOUVER, British Columbia, Feb. 05, 2021 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “ Company ” or “ WPD ”) a clinical-stage pharmaceutical company, is pleased to announce that that Moleculin Biotech Inc. (NASDAQ:MBRX) ...